Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dry eye disease
Biotech
Aldeyra dry eye disease decision hit by FDA delay
The delay comes after the regulator sent a draft label for the drug candidate to the company in early December and Aldeyra responded with comments.
Darren Incorvaia
Dec 16, 2025 11:55am
Théa pens $280M deal for Iolyx's phase 3-ready eye disease drug
Dec 3, 2025 8:25am
Stuart sees dry eye disease drug fail ph. 3 study, plans another
Jun 24, 2025 9:26am
Aldeyra posts hit, miss for dry eye drug, plans FDA filing
May 6, 2025 7:05am
Aldeyra’s dry eye drug suffers second FDA rejection
Apr 3, 2025 8:46am
Bausch + Lomb pens $485M-plus biobucks pact with City Tx
Jan 10, 2025 6:37am
